MA33076B1 - Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer - Google Patents

Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer

Info

Publication number
MA33076B1
MA33076B1 MA33027A MA33027A MA33076B1 MA 33076 B1 MA33076 B1 MA 33076B1 MA 33027 A MA33027 A MA 33027A MA 33027 A MA33027 A MA 33027A MA 33076 B1 MA33076 B1 MA 33076B1
Authority
MA
Morocco
Prior art keywords
treatment
cancer
secretase inhibitor
gamma secretase
patient
Prior art date
Application number
MA33027A
Other languages
Arabic (ar)
English (en)
Inventor
John Frederick Boylan
Leopoldo Ladores Luistro Iii
Kathryn E Packman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40365425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33076(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33076B1 publication Critical patent/MA33076B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR UN PROCÉDÉ DE TRAITEMENT D'UN PATIENT AYANT UN CANCER, COMPRENANT L'ADMINISTRATION AU PATIENT D'UNE QUANTITÉ THÉRAPEUTIQUEMENT EFFICACE DE COMPOSÉ (1), OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, AYANT LA FORMULE : LA PRÉSENTE INVENTION PORTE ÉGALEMENT SUR UN COFFRET CONTENANT LE COMPOSÉ CI-DESSUS, AINSI QUE SUR L'UTILISATION DU COMPOSÉ (1) POUR LA FABRICATION DE MÉDICAMENTS POUR LE TRAITEMENT DU CANCER SELON LES DOSAGES ET LES PROGRAMMES SPÉCIFIQUEMENT DÉCRITS ICI.
MA33027A 2008-01-11 2009-01-05 Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer MA33076B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2044708P 2008-01-11 2008-01-11
PCT/EP2009/050047 WO2009087130A1 (fr) 2008-01-11 2009-01-05 Utilisation d'un inhibiteur de la gamma-sécrétase pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA33076B1 true MA33076B1 (fr) 2012-03-01

Family

ID=40365425

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33027A MA33076B1 (fr) 2008-01-11 2009-01-05 Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer

Country Status (17)

Country Link
US (1) US20090181944A1 (fr)
EP (1) EP2244713A1 (fr)
JP (3) JP5612482B2 (fr)
KR (2) KR20140007979A (fr)
CN (1) CN101909633B (fr)
AR (1) AR072442A1 (fr)
AU (1) AU2009203776A1 (fr)
BR (1) BRPI0906831A2 (fr)
CA (1) CA2710913A1 (fr)
CL (1) CL2009000040A1 (fr)
CR (1) CR11510A (fr)
IL (1) IL206361A0 (fr)
MA (1) MA33076B1 (fr)
RU (1) RU2010133489A (fr)
TW (1) TW200936139A (fr)
WO (1) WO2009087130A1 (fr)
ZA (1) ZA201004859B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (fr) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Génération de cellules de l'oreille interne
US10143711B2 (en) 2008-11-24 2018-12-04 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
US8309299B2 (en) * 2010-05-19 2012-11-13 Hoffmann-La Roche Inc. Combination therapy and method for assessing resistance to treatment
WO2012050370A2 (fr) * 2010-10-15 2012-04-19 성균관대학교산학협력단 Composition pour prévenir ou traiter la polyarthrite rhumatoïde contenant un inhibiteur de sécrétase gamma en tant que composant actif
KR101330184B1 (ko) 2010-10-15 2013-11-15 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
US20120114638A1 (en) * 2010-11-08 2012-05-10 John Boylan Combination therapy
US20120225860A1 (en) * 2011-03-02 2012-09-06 John Frederick Boylan Method for administration of a gamma secretase inhibitor
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
AR087107A1 (es) 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
EP3970725B1 (fr) 2012-09-07 2025-08-20 Massachusetts Eye & Ear Infirmary Un inhibiteur de la gamma-sécrétase pour le traitement de la perte auditive
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
JP2015529250A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ フルオロアルキルジベンゾジアゼピノン化合物
WO2014047390A1 (fr) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Composés hétérocycliques tricycliques utilisables en tant qu'inhibiteurs du récepteur notch
CN105308030A (zh) 2012-09-21 2016-02-03 百时美施贵宝公司 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
WO2014047397A1 (fr) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Composés de fluoralkyl- et de fluorocycloalkyl-1,4-benzodiazépinone utilisables en tant qu'inhibiteurs du récepteur notch
EP2897944B1 (fr) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Composés de 1,5-benzodiazépinone substituée
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
CN104968648A (zh) 2012-09-21 2015-10-07 百时美施贵宝公司 1,4-苯并二氮杂*酮化合物的前药
US9242940B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
JP2016515625A (ja) 2013-04-04 2016-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 増殖性疾患を治療するための併用療法
US20160304959A1 (en) * 2013-12-17 2016-10-20 Rush University Medical Center Compositions and methods for treating diabetic nephropathy
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP3212773B1 (fr) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Administration efficace de molécules thérapeutiques en direction de cellules de l'oreille interne
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CA3013038A1 (fr) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion et differenciation des cellules de support de l'oreille interne, et methodes d'utilisation de ces dernieres
KR102418766B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
WO2017200762A2 (fr) 2016-05-16 2017-11-23 The General Hospital Corporation Cellules souches de voies respiratoires humaines en ingénierie épithéliale pulmonaire
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CN110337291A (zh) 2016-12-16 2019-10-15 帕珀莱恩医疗公司 治疗耳蜗突触病变的方法
EP3706754A1 (fr) 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
KR102094442B1 (ko) 2018-06-28 2020-03-27 성균관대학교산학협력단 알쯔하이머성 치매의 예방 또는 치료용 물질 및 이를 포함하는 조성물
WO2022067185A1 (fr) * 2020-09-27 2022-03-31 Veru Inc. Méthodes de traitement du cancer de la prostate à effets secondaires minimes
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6012A (en) * 1849-01-09 Lithographing co
AU2004270361B2 (en) * 2003-09-09 2009-06-25 F. Hoffmann-La Roche Ag Malonamide derivatives blocking the activity of gama-secretase
US7211573B2 (en) * 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
MX2007009908A (es) * 2005-02-15 2007-10-03 Novartis Vaccines & Diagnostic Metodos para tratar linfomas utilizando una combinacion de un agente quimioterapeutico e il-2 y opcionalmente un anticuerpo anti-cd20.
EP1888051A2 (fr) * 2005-05-17 2008-02-20 MERCK SHARP & DOHME LTD. Cyclohexyl sulfone a substitution sulfonamido pour le traitement du cancer
US20080058316A1 (en) * 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors

Also Published As

Publication number Publication date
IL206361A0 (en) 2010-12-30
JP2011509273A (ja) 2011-03-24
AU2009203776A1 (en) 2009-07-16
WO2009087130A1 (fr) 2009-07-16
JP2014221772A (ja) 2014-11-27
EP2244713A1 (fr) 2010-11-03
TW200936139A (en) 2009-09-01
CR11510A (es) 2010-09-13
KR20100101624A (ko) 2010-09-17
CA2710913A1 (fr) 2009-07-16
RU2010133489A (ru) 2012-02-20
KR20140007979A (ko) 2014-01-20
BRPI0906831A2 (pt) 2019-09-24
JP5612482B2 (ja) 2014-10-22
US20090181944A1 (en) 2009-07-16
JP2013241443A (ja) 2013-12-05
AR072442A1 (es) 2010-09-01
ZA201004859B (en) 2011-03-30
CN101909633A (zh) 2010-12-08
CN101909633B (zh) 2012-05-30
CL2009000040A1 (es) 2010-02-12

Similar Documents

Publication Publication Date Title
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EA200800538A1 (ru) Терапевтические соединения
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
PH12016502355B1 (en) Pharmaceutical composition
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
WO2009039397A3 (fr) Amides substitués, procédé pour les préparer et procédé pour les utiliser
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200801997A1 (ru) Новые соединения
TW200806299A (en) Treatment of pain
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
ATE533489T1 (de) Behandlung von multiplem myelom
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
EA201170344A1 (ru) Азаиндольные ингибиторы iap
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي